STaRT Registry  

This trial aims to measure the effectiveness and safety of GammaTile™ Surgically Targeted Radiation Therapy (STaRT) through clinical and patient-reported outcomes. To qualify for entry, your treatment must include the maximum safe resection of intracranial neoplasm(s) and implantation of GammaTiles™.  If you feel you qualify for this trial, complete the clinical trial form or talk with your physician about other entry requirements.

GESTALT  

This trial seeks to explore the effectiveness of GammaTitles™ in diagnosed glioblastoma patients and the safety of dose escalation and intensification. To qualify for entry, you must be at least 18 years old and diagnosed with glioblastoma.  If you feel you qualify for this trial, complete the clinical trial form or talk with your physician about other entry requirements.

NRG-BN012  

This trial studies the effect of stereotactic radiosurgery, a form of radiation therapy that applies radiation only to the areas of cancer and not the surrounding brain tissue, before and after surgery in patients with cancer that has spread to the brain. To qualify for entry, you must be at least 18 years old with confirmed brain metastases. If you feel you qualify for this trial, complete the clinical trial form or talk with your physician about other entry requirements.

OCEANIC-STROKE  

This trial studies the effectiveness of Asundexian, an anticoagulant, to prevent Ischemic strokes. To qualify for entry, you must be at least 18 years old. If you feel you qualify for this trial, complete the clinical trial form or talk with your physician about other entry requirements.

REcurrent Brain Metastases After SRS Trial

This trial examines how well two different treatment plans work for patients with brain metastases. To qualify for entry, you must be at least 18 years old and have brain metastases confirmed by imaging, stemming from cancer outside the central nervous system. If you feel you qualify for this trial, complete the clinical trial form or talk with your physician about other entry requirements.

Telix’s Investigational Glioma Imaging Agent

This trial uses a new experimental investigational positron emission tomography (PET) agent called TLX101-CDx (Pixclara®, F-floretyrosine or F-FET) to look at the brain and spot gliomas, providing a more rapid and conclusive diagnosis for imaging progressive or recurrent gliomas. To qualify for entry, you must have a previous diagnosis of glioma. If you feel you qualify for this trial, complete the clinical trial form or talk with your physician about other entry requirements.